Company / SG&A Expense
FILANA THERAPEUTICS, INC. SG&A Expense History
FY2011-FY2015 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$4.8M
FY2015
5-year range
$4.8M / $14.8M
FY2011-FY2015
Trend
-32.7%
vs FY2014
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 5 years, ranging from $5M in FY2015 to $15M in FY2012.
Based on SEC 10-K filings.
$5M in FY2015 with a 3-year CAGR of -31.1%.
Improved from $7M to $5M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -31.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -31.1%, indicating a declining trend.
- In FY2015, sg&a expense decreased 32.7% year-over-year.
- Peak sg&a expense was recorded in FY2012.
Company context
Key Data Points
- Altman Z-Score 3.76 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2015 | $4.8M | -32.7% |
| FY2014 | $7.2M | +7.2% |
| FY2013 | $6.7M | -54.6% |
| FY2012 | $14.8M | +136.0% |
| FY2011 | $6.3M | - |
As of FY2015 · SEC 10-K · Updated Jun 24, 2026